Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Quality-Adjusted Survival (Q-TWiST) Analysis of Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia Treated with Rituximab Plus Fludarabine and Cyclophosphamide (R-FC) Versus FC Alone.

Tadeusz Robak, MD, PhD, Rick Aultman, MSc, Stats, Stephan H.K. Oertel, MD, Emma SC Carr, BSc, MSc, PhD

Blood (2009) 114 (22): 1368.

https://doi.org/10.1182/blood.V114.22.1368.1368

Published: 2009

Journal Articles

Long-Term Health Outcomes and Costs Associated with the Use of Rituximab in Combination with fludarabine and Cyclophosphamide (R-FC) in the Treatment of relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) in Poland.

Tadeusz Robak, MD, PhD, Monika Szkultecka-Dêbek, MD, Rick Aultman, MSc, Emma S Carr, MSc, PhD, P. Kawalec, MD

Blood (2009) 114 (22): 4528.

https://doi.org/10.1182/blood.V114.22.4528.4528

Published: 2009

Journal Articles

A UK Cost-Effectiveness Analysis Comparing First Line Treatment with Rituximab in Combination with Fludarabine and Cyclophosphamide Versus Fludarabine and Cyclophosphamide Alone in Chronic Lymphocytic Leukemia (CLL) Patients

Konstantinos Papadakis, MSc, David Oscier, Emma SC Carr, BSc, MSc, PhD, Gavin Lewis, Rick Aultman, MSc, Stats

Blood (2008) 112 (11): 2392.

https://doi.org/10.1182/blood.V112.11.2392.2392

Published: 2008

Journal Articles

Treatment Effect of First Line Rituximab, Fludarabine and Cyclosphosphamide in a Chronic Lymphocytic Leukemia Patient Cohort: An Evaluation of Prognostic Factors, Estimated Life Expectancy and Economic Outcomes

Emma Carr, PhD, Susan Lerner, M.S., RHAI, Rick Aultman, MSc, Ute Weisgerber-Kriegl, PhD, Michael Keating, MB, BS

Blood (2008) 112 (11): 2396.

https://doi.org/10.1182/blood.V112.11.2396.2396

Published: 2008

Journal Articles

The Cost-Effectiveness of Rituximab, Cyclophosphamide, Vincristine and Prednisolone (RCVP) Compared with CVP for the Treatment of Follicular Non-Hodgkin’s Lymphoma (NHL) in the UK.

Gavin Lewis, MSc, Robert E. Marcus, MB, Stephen J. Proctor, FRCP FRCPath, Marlene Gyldmark, James Creeden, MD PhD, Rick Aultman, MSc, Fred Jost, MSc

Blood (2006) 108 (11): 345.

https://doi.org/10.1182/blood.V108.11.345.345

Published: 2006

NARROW

Quality-Adjusted Survival (Q-TWiST) Analysis of Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia Treated with Rituximab Plus Fludarabine and Cyclophosphamide (R-FC) Versus FC Alone.

Long-Term Health Outcomes and Costs Associated with the Use of Rituximab in Combination with fludarabine and Cyclophosphamide (R-FC) in the Treatment of relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) in Poland.

A UK Cost-Effectiveness Analysis Comparing First Line Treatment with Rituximab in Combination with Fludarabine and Cyclophosphamide Versus Fludarabine and Cyclophosphamide Alone in Chronic Lymphocytic Leukemia (CLL) Patients

Treatment Effect of First Line Rituximab, Fludarabine and Cyclosphosphamide in a Chronic Lymphocytic Leukemia Patient Cohort: An Evaluation of Prognostic Factors, Estimated Life Expectancy and Economic Outcomes

The Cost-Effectiveness of Rituximab, Cyclophosphamide, Vincristine and Prednisolone (RCVP) Compared with CVP for the Treatment of Follicular Non-Hodgkin’s Lymphoma (NHL) in the UK.

Email alerts

ASH Publications

American Society of Hematology

Quality-Adjusted Survival (Q-TWiST) Analysis of Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia Treated with Rituximab Plus Fludarabine and Cyclophosphamide (R-FC) Versus FC Alone.

Long-Term Health Outcomes and Costs Associated with the Use of Rituximab in Combination with fludarabine and Cyclophosphamide (R-FC) in the Treatment of relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) in Poland.

A UK Cost-Effectiveness Analysis Comparing First Line Treatment with Rituximab in Combination with Fludarabine and Cyclophosphamide Versus Fludarabine and Cyclophosphamide Alone in Chronic Lymphocytic Leukemia (CLL) Patients

Treatment Effect of First Line Rituximab, Fludarabine and Cyclosphosphamide in a Chronic Lymphocytic Leukemia Patient Cohort: An Evaluation of Prognostic Factors, Estimated Life Expectancy and Economic Outcomes

The Cost-Effectiveness of Rituximab, Cyclophosphamide, Vincristine and Prednisolone (RCVP) Compared with CVP for the Treatment of Follicular Non-Hodgkin’s Lymphoma (NHL) in the UK.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only